Eucalyptus (Eucalyptus globulus)

Eucalyptus (Eucalyptus globulus) — scientific infographic poster
Botanical illustration of Eucalyptus globulus showing a branch with lance-shaped leaves, cream-colored flower clusters, seed capsules in cross-section, and seeds
Eucalyptus globulus — leaves, flowers, seed capsules, and seeds

Table of Contents

  1. Australian Aboriginal History and Global Spread
  2. Key Antibacterial Compounds
  3. Mechanism of Antibacterial Action
  4. Bacteria Targeted
  5. Research Studies and Clinical Evidence
  6. Respiratory Antibacterial Applications
  7. Hospital and Clinical Use
  8. Wound Care and Topical Applications
  9. Oral Health
  10. Eucalyptus Species Comparison
  11. Synergistic Effects
  12. Other Health Benefits
  13. Forms and Preparations
  14. Traditional Use and Doses Studied
  15. Safety and Contraindications
  16. Key Research Papers
  17. Featured Videos

Australian Aboriginal History and Global Spread

Eucalyptus has been a cornerstone of Australian Aboriginal medicine for tens of thousands of years — its red gum (kino) used as an astringent wound wash and its leaves infused for fevers, colds, and coughs. From the 1850s the German-Australian botanist Ferdinand von Mueller carried Eucalyptus globulus to Europe, Africa, Asia, and the Americas, the pharmacist Joseph Bosisto founded the first commercial eucalyptus-oil industry, and in 1870 the French chemist François Stanislas Cloez isolated and named its key compound, eucalyptol (1,8-cineole). — the fuller story is told in the dedicated History & Traditional Use article.

Key Antibacterial Compounds

The antibacterial potency of Eucalyptus globulus essential oil derives from a complex mixture of volatile terpenoid compounds. Each contributes to the overall antimicrobial effect through distinct biochemical mechanisms, and their combined action produces broad-spectrum antibacterial activity.

The relative proportions of these compounds vary significantly based on the eucalyptus species, the geographical region of cultivation, altitude, soil composition, rainfall, and the time of year the leaves are harvested. Pharmacopoeia-grade E. globulus oil typically requires a minimum 1,8-cineole content of 70% to meet medicinal standards.

Mechanism of Antibacterial Action

Eucalyptus oil exerts its antibacterial effects through multiple simultaneous mechanisms, making it difficult for bacteria to develop resistance. Unlike single-target pharmaceutical antibiotics, eucalyptus attacks bacterial cells on several fronts at once.

Membrane Disruption

The primary antibacterial mechanism of eucalyptus oil involves the disruption of bacterial cell membrane integrity. The lipophilic terpenoid compounds in eucalyptus oil, particularly eucalyptol and alpha-pinene, integrate into the phospholipid bilayer of bacterial cell membranes. This integration causes expansion and destabilization of the membrane, increasing its permeability. As a result, essential intracellular contents including ions, adenosine triphosphate (ATP), and proteins leak out of the bacterial cell, collapsing the proton motive force and halting cellular energy production. The cell loses its ability to maintain homeostasis and dies.

Studies using electron microscopy have demonstrated visible morphological changes in bacteria exposed to eucalyptus oil, including membrane blebbing, cytoplasmic condensation, and complete cell lysis. The effect is concentration-dependent, with sub-inhibitory concentrations causing partial membrane damage that sensitizes bacteria to other antimicrobial agents.

Mucus Penetration

A property unique to eucalyptus among commonly used antibacterial herbs is its exceptional ability to penetrate mucus barriers. The respiratory tract is lined with a thick mucus layer that serves as a physical barrier against pathogens but also shields bacteria once they become embedded within it. Eucalyptol possesses powerful mucolytic activity, breaking down the disulfide bonds in mucin glycoproteins that give mucus its viscous, gel-like consistency. By liquefying and thinning the mucus layer, eucalyptol exposes embedded bacteria to both the immune system and to the oil's own antibacterial compounds.

This mucolytic action distinguishes eucalyptus from other antibacterial essential oils such as tea tree or oregano, which lack significant mucus-penetrating capacity. Clinical studies have demonstrated that inhaled eucalyptol reaches measurable concentrations in bronchial mucus within 20 minutes and maintains therapeutically active levels for several hours.

Respiratory Biofilm Disruption

Many respiratory pathogens, including Pseudomonas aeruginosa, Haemophilus influenzae, and Streptococcus pneumoniae, form biofilms on the epithelial surfaces of the airways. These biofilms are structured communities of bacteria encased in a self-produced matrix of polysaccharides, proteins, and extracellular DNA. Biofilm-embedded bacteria are 100 to 1,000 times more resistant to antibiotics than their free-floating (planktonic) counterparts.

Eucalyptus oil has demonstrated the ability to disrupt both the formation and the structural integrity of established biofilms. Eucalyptol interferes with quorum sensing, the chemical communication system bacteria use to coordinate biofilm formation and virulence factor production. By disrupting quorum sensing signals, eucalyptol prevents bacteria from establishing the cooperative behaviors necessary for biofilm development. Against pre-formed biofilms, the oil's lipophilic compounds penetrate the extracellular matrix, destabilizing its structure and exposing the resident bacteria to immune clearance and antibiotic treatment.

Bacteria Targeted

Eucalyptus oil has demonstrated antibacterial activity against a broad range of clinically significant pathogens. The following bacteria have been studied extensively in laboratory and, in some cases, clinical settings:

Research Studies and Clinical Evidence

The antibacterial properties of eucalyptus have been documented in numerous peer-reviewed studies across microbiology, pharmacology, and clinical medicine journals.

Clinical Microbiology and Infection

A study published in Clinical Microbiology and Infection (Salari 2006) tested a Eucalyptus globulus leaf extract (not the essential oil) against bacteria isolated from patients with respiratory tract disorders: 56 isolates of Staphylococcus aureus, 25 of Streptococcus pyogenes, 12 of Streptococcus pneumoniae and 7 of Haemophilus influenzae. For S. aureus, the minimum inhibitory concentration (MIC) was 64 mg/L for half the isolates (MIC50) and 128 mg/L for 90% of them (MIC90), and the minimum bactericidal concentration (MBC) was 512 mg/L; the three other species were inhibited at lower concentrations. The authors concluded that further studies of the extract's possible role in respiratory tract infection are warranted.

Phytomedicine

Studies published in Phytomedicine have investigated the mechanism of eucalyptus oil's antibacterial action at the molecular level. Using flow cytometry, fluorescence microscopy, and membrane permeability assays, researchers demonstrated that eucalyptol causes dose-dependent disruption of bacterial membrane potential and integrity. The oral cineole trial in acute sinusitis appeared elsewhere: Kehrl 2004 in Laryngoscope (152 patients, two 100-mg capsules three times daily for 7 days) found statistically significant improvement in symptom scores compared to placebo after 4 and 7 days of treatment.

Drug-Resistant Infections and Air Disinfection

Eucalyptus oil has a long traditional use as an antiseptic (see Surgical Wound Antiseptic History below), and practitioners describe it as a possible add-on to conventional antibiotics against multidrug-resistant infections.

Additional studies have examined the efficacy of eucalyptus oil vapor in reducing airborne bacterial counts in clinical environments, demonstrating significant reductions in colony-forming units (CFU) after 30 and 60 minutes of exposure to eucalyptus oil diffusion.

Respiratory Antibacterial Applications

The respiratory tract represents the primary therapeutic domain for eucalyptus-based antibacterial interventions. The combination of direct antibacterial activity, mucolytic action, and anti-inflammatory effects makes eucalyptus uniquely suited for respiratory infections.

Sinusitis

Acute and chronic sinusitis frequently involve bacterial infection with S. pneumoniae, H. influenzae, and M. catarrhalis. Multiple randomized controlled trials have demonstrated that oral cineole capsules (200 mg three times daily) significantly reduce sinusitis symptoms including nasal congestion, headache, and facial pain compared to placebo. In these trials, cineole was used as monotherapy without concurrent antibiotics, and patients treated with cineole showed faster symptom resolution and lower rates of antibiotic rescue therapy. The mucolytic action of cineole promotes drainage of infected sinus contents while its antibacterial properties directly combat the causative organisms.

Bronchitis

In acute bronchitis, eucalyptus-based preparations help by thinning bronchial secretions, facilitating expectoration of infected mucus, and exerting direct antibacterial effects against common causative organisms. Clinical trials using cineole capsules as adjunctive therapy alongside standard treatment for acute bronchitis have shown significant reductions in cough frequency, sputum production, and duration of illness. For chronic bronchitis and acute exacerbations of chronic obstructive pulmonary disease, cineole has demonstrated the ability to reduce exacerbation frequency when used as long-term maintenance therapy.

Pneumonia Support

While eucalyptus is not a substitute for antibiotic therapy in bacterial pneumonia, it serves a valuable supportive role. Steam inhalation with eucalyptus oil helps mobilize secretions in the lower respiratory tract, improving airway clearance and reducing the bacterial burden in bronchial mucus. The anti-inflammatory properties of eucalyptol reduce excessive inflammatory responses in the lung parenchyma, potentially limiting tissue damage. Some integrative medicine practitioners recommend eucalyptus steam inhalation as a complementary therapy alongside prescribed antibiotics for community-acquired pneumonia.

Cineole Clinical Trials

Pure 1,8-cineole has been the subject of over 20 randomized controlled clinical trials for respiratory conditions. The most extensively studied formulation is enteric-coated cineole capsules at 200 mg doses. Key findings across these trials include a 50–70% improvement in mucociliary clearance measured by saccharin transit time, significant reduction in inflammatory markers including leukotrienes, prostaglandins, and tumor necrosis factor-alpha in bronchial lavage fluid, and faster resolution of radiographic findings in patients with lower respiratory tract infections.

Steam Inhalation

Traditional steam inhalation with eucalyptus oil remains a widely used method of delivering antibacterial compounds directly to the respiratory mucosa. Adding 3–5 drops of eucalyptus essential oil to a bowl of hot water and inhaling the vapor for 10–15 minutes allows eucalyptol and other volatile compounds to reach the nasal passages, sinuses, pharynx, larynx, and upper bronchial tree. Studies using gas chromatography-mass spectrometry (GC-MS) have confirmed that therapeutically relevant concentrations of eucalyptol are achieved in bronchial mucus within 20 minutes of steam inhalation and persist for 2–4 hours.

Hospital and Clinical Use

Air Disinfection Research

Multiple studies have investigated the potential of eucalyptus oil vapor for reducing airborne bacterial contamination in clinical settings. Research conducted in hospital wards, operating theaters, and intensive care units has demonstrated that diffusion of eucalyptus oil into ambient air produces significant reductions in airborne bacterial colony counts. Studies using settle plate methodology and active air sampling have reported 40–70% reductions in total airborne bacterial CFU after 60 minutes of eucalyptus oil diffusion at concentrations of 0.05–0.1 mL per cubic meter of air. These findings have prompted interest in eucalyptus-based air disinfection as a complementary strategy for reducing hospital-acquired infections, particularly in resource-limited settings where advanced air filtration systems may be unavailable.

Surgical Wound Antiseptic History

Eucalyptus oil has a distinguished history in surgical antisepsis. Following Joseph Lister's pioneering work on antiseptic surgery in the 1860s, eucalyptus oil was adopted alongside carbolic acid as a wound disinfectant in operating theaters throughout the British Empire. Australian military surgeons used eucalyptus-based antiseptic preparations extensively during the Boer War and World War I, where they reported favorable wound healing outcomes compared to other available antiseptics. Eucalyptus oil's advantage lay in its combination of antibacterial activity with relatively low tissue toxicity compared to phenol and other chemical antiseptics of the era. By the early 20th century, eucalyptus oil was listed in the British Pharmacopoeia and multiple colonial pharmacopoeias as an approved wound antiseptic.

Hospital-Acquired Infection Studies

Contemporary research has evaluated eucalyptus oil's potential role in combating hospital-acquired infections (HAIs), which affect approximately 1 in 31 hospital patients in developed countries. Studies have examined eucalyptus oil-based surface disinfectants, hand hygiene formulations, and air purification systems. Results indicate that eucalyptus oil solutions at concentrations of 1–5% effectively eliminate common nosocomial pathogens including methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus (VRE), and Clostridium difficile from hard surfaces within 10 minutes of contact. However, its relatively slow kill time compared to synthetic disinfectants limits its use as a primary hospital-grade disinfectant, positioning it more as a complementary or adjunctive agent.

Wound Care and Topical Applications

Burns

Eucalyptus oil has been investigated for use in burn wound management due to its combined antibacterial and anti-inflammatory properties. Burn wounds are highly susceptible to bacterial colonization, particularly by S. aureus, P. aeruginosa, and Acinetobacter baumannii. Studies using animal burn wound models have demonstrated that topical application of diluted eucalyptus oil (2–5% in a carrier) reduces bacterial colonization counts by 2–3 log units compared to untreated controls and promotes faster wound epithelialization. The anti-inflammatory action of eucalyptol helps reduce excessive inflammation in the burn wound bed, which can impede healing.

Ulcers

Chronic skin ulcers, including diabetic foot ulcers and venous leg ulcers, represent a significant clinical challenge due to persistent bacterial biofilm infection. Eucalyptus oil's biofilm-disrupting properties make it a promising adjunctive agent for chronic wound management. In vitro studies using wound-relevant biofilm models have demonstrated that eucalyptus oil penetrates and disrupts established biofilms of S. aureus and P. aeruginosa, the two most common colonizers of chronic wounds. Clinical case series have reported improved healing outcomes when eucalyptus-based wound dressings are used as part of a comprehensive wound care protocol.

Insect Bites

Diluted eucalyptus oil applied topically to insect bites provides both antibacterial protection against secondary infection and local analgesic and anti-inflammatory effects. The cooling sensation produced by eucalyptol activates TRPM8 cold-sensitive receptors in the skin, providing symptomatic relief from itching and pain. The antibacterial action prevents opportunistic infection of bite wounds, which is particularly important in tropical and subtropical regions where insect bites frequently become infected.

Surgical Dressings

Modern wound care research has explored the incorporation of eucalyptus oil into advanced wound dressing materials. Eucalyptus oil has been successfully incorporated into hydrogels, nanofiber mats, chitosan films, and alginate dressings, providing sustained-release antibacterial activity at the wound surface. These eucalyptus-impregnated dressings maintain antibacterial activity for 24–72 hours depending on the delivery system, reducing the frequency of dressing changes and associated wound disturbance. Studies have demonstrated that eucalyptus-loaded nanofiber dressings inhibit growth of wound-relevant pathogens while maintaining cytocompatibility with human fibroblasts and keratinocytes.

Oral Health

Mouthwash Studies

Eucalyptol is a key active ingredient in several commercially available antiseptic mouthwashes, most notably the essential-oil mouthwashes, where it is combined with thymol, menthol, and methyl salicylate. Clinical trials comparing eucalyptol-containing mouthwashes to placebo and to chlorhexidine (the gold-standard prescription mouthwash) have demonstrated significant reductions in plaque accumulation, gingivitis severity, and total oral bacterial counts. While eucalyptol-based mouthwashes are generally less potent than chlorhexidine for short-term plaque control, they offer advantages for long-term use due to their lack of tooth staining and taste disturbance side effects.

Dental Bacteria

Eucalyptus oil demonstrates antibacterial activity against the major oral pathogens responsible for dental caries and periodontal disease. In vitro studies have shown significant inhibition of Streptococcus mutans (the primary caries-causing bacterium), Porphyromonas gingivalis (a key periodontal pathogen), Fusobacterium nucleatum (involved in oral biofilm maturation), and Aggregatibacter actinomycetemcomitans (associated with aggressive periodontitis). The biofilm-disrupting properties of eucalyptus oil are particularly relevant in oral health, as dental plaque is a bacterial biofilm, and disruption of its matrix structure enhances the effectiveness of mechanical hygiene measures.

Halitosis

Eucalyptus oil is effective against the volatile sulfur compound-producing bacteria responsible for halitosis. The primary halitosis-causing organisms, including P. gingivalis, Prevotella intermedia, and Treponema denticola, are susceptible to eucalyptol at concentrations achieved in commercially available mouthwashes. Clinical studies have demonstrated significant reductions in organoleptic halitosis scores and volatile sulfur compound measurements following the use of eucalyptol-containing oral rinses. The fresh, mentholated character of eucalyptol also provides immediate masking of malodor while the antibacterial effect reduces odor-producing bacterial populations over time.

Eucalyptus Species Comparison

The genus Eucalyptus comprises over 700 species, but only a handful are used medicinally. The three most commonly employed species differ significantly in their chemical composition and antibacterial potency.

Eucalyptus globulus (Blue Gum)

E. globulus is the most widely used species in Western herbal medicine and pharmaceutical preparations. Its essential oil contains the highest concentration of 1,8-cineole among commonly cultivated species, typically 60–90%. This high eucalyptol content gives E. globulus the strongest overall antibacterial activity in standardized in vitro testing. It is the species most commonly referenced in pharmacopoeia monographs and the most extensively studied in clinical trials. E. globulus oil has the most potent mucolytic action and is considered the species of choice for respiratory antibacterial applications. Its aroma is strong, sharp, and camphoraceous.

Eucalyptus radiata (Narrow-Leaved Peppermint)

E. radiata contains a moderate concentration of 1,8-cineole, typically 60–75%, along with higher proportions of alpha-terpineol and other monoterpenols compared to E. globulus. While its direct antibacterial potency is somewhat lower than E. globulus in disc diffusion assays, E. radiata is better tolerated by children and individuals with sensitive respiratory tracts. It is often preferred by aromatherapists for pediatric applications and for patients who find E. globulus too stimulating. Its aroma is softer, more peppery, and less camphoraceous.

Eucalyptus citriodora (Lemon-Scented Gum)

E. citriodora has a fundamentally different chemical profile, with its oil dominated by citronellal (65–85%) rather than 1,8-cineole, which is present at only 1–5%. This gives it a distinctly lemony aroma quite unlike other eucalyptus species. While E. citriodora shows lower direct antibacterial activity against respiratory pathogens compared to E. globulus, it demonstrates stronger activity against certain Gram-negative bacteria and possesses superior antifungal properties. It is also a more effective insect repellent, with the U.S. Centers for Disease Control and Prevention (CDC) recognizing oil of lemon eucalyptus as an effective alternative to DEET. For antibacterial applications specifically, E. citriodora is generally considered the least potent of the three common medicinal species.

Range bars for three medicinal eucalyptus species on a common percentage axis: E. globulus oil is 60 to 90 percent 1,8-cineole, E. radiata 60 to 75 percent, and E. citriodora only 1 to 5 percent cineole but 65 to 85 percent citronellal; a dashed line at 70 percent marks the pharmacopoeia minimum cineole content for E. globulus oil, which falls inside that species' own 60 to 90 percent range. WHICH COMPOUND DOMINATES EACH SPECIES share of the essential oil · ranges shift with origin, climate and harvest time pharmacopoeia minimum: 70% cineole E. globulus blue gum strongest in vitro, first choice for respiratory use 1,8-cineole 60–90% E. radiata narrow-leaved peppermint somewhat lower potency, better tolerated by children 1,8-cineole 60–75% E. citriodora lemon-scented gum least antibacterial of the three, stronger antifungal cineole only 1–5% citronellal 65–85% 20%40%60% 80%100% share of the oil → ONE NAME, THREE OILS cineole carries the respiratory action it is the compound most responsible for reaching bacteria in mucus the two cineole oils overlap radiata trades a little potency for a gentler, softer oil lemon eucalyptus is another oil citronellal, not cineole: weaker on respiratory pathogens, better as an antifungal and insect repellent the 70% standard sits inside the globulus range, so not every globulus oil meets it ranges and potency comparisons as this page gives them · the 70% pharmacopoeia standard is set for E. globulus oil

Synergistic Effects

One of the most promising areas of eucalyptus antibacterial research involves its synergistic interactions with other essential oils and with conventional antibiotic drugs. Synergism occurs when the combined effect of two agents exceeds the sum of their individual effects, allowing lower doses of each to achieve equivalent or superior antibacterial activity.

With Tea Tree Oil

The combination of eucalyptus oil and tea tree oil (Melaleuca alternifolia) produces consistently synergistic antibacterial effects against both Gram-positive and Gram-negative bacteria. Tea tree oil's primary compound, terpinen-4-ol, acts through membrane disruption mechanisms that complement eucalyptol's activity. Checkerboard assay studies have demonstrated FICI values of 0.25–0.50 against methicillin-resistant Staphylococcus aureus, indicating strong synergism. The combination is particularly effective for topical wound care applications, where the two oils together provide broader-spectrum coverage than either alone.

With Thyme Oil

Thyme oil (Thymus vulgaris), rich in thymol and carvacrol, demonstrates powerful synergism with eucalyptus oil. The phenolic compounds in thyme oil attack bacterial membranes through a different mechanism than eucalyptol's terpenoid ether structure, and the two attack modalities together produce rapid bactericidal effects. Studies have shown that the eucalyptus-thyme combination achieves kill times 2–4 times faster than either oil alone against common respiratory pathogens.

With Peppermint Oil

Peppermint oil (Mentha piperita), containing menthol and menthone, enhances eucalyptus oil's antibacterial activity while adding additional cooling and analgesic properties. The combination is particularly useful in respiratory applications, where menthol's bronchodilatory effects complement eucalyptol's mucolytic action. The two oils together improve both symptom relief and bacterial clearance in upper respiratory tract infections.

With Conventional Antibiotics

Perhaps the most clinically significant synergistic interactions involve eucalyptus oil combined with conventional antibiotic drugs. Laboratory (test-tube) reports describe sub-inhibitory concentrations of eucalyptus oil restoring the effectiveness of antibiotics against resistant organisms; these findings have not been tested in people. For example, the combination of eucalyptus oil with ampicillin is reported to show synergistic effects against methicillin-resistant Staphylococcus aureus isolates that are fully resistant to ampicillin alone. Similar synergistic interactions are reported with gentamicin against resistant P. aeruginosa and with ciprofloxacin against resistant E. coli. The proposed mechanism involves eucalyptus oil's disruption of bacterial membrane efflux pumps, which are a primary resistance mechanism through which bacteria actively pump antibiotics out of their cells.

Other Health Benefits

Beyond its antibacterial properties, eucalyptus offers a range of additional health benefits that contribute to its overall therapeutic value.

Forms and Preparations

Traditional Use and Doses Studied

Inhalation

Topical Dilution

Chest Rub Application

Safety and Contraindications

While eucalyptus is widely considered safe when used appropriately in external and inhalation applications, several important safety findings apply.

Key Research Papers

  1. Sadlon, A.E. and Lamson, D.W. "Immune-modifying and antimicrobial effects of eucalyptus oil and simple inhalation devices." Alternative Medicine Review, 15(1): 33–47, 2010.
  2. Cermelli, C., Fabio, A., Fabio, G., and Quaglio, P. "Effect of eucalyptus essential oil on respiratory bacteria and viruses." Current Microbiology, 56(1): 89–92, 2008.
  3. Kehrl, W., Sonnemann, U., and Dethlefsen, U. "Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial." Laryngoscope, 114(4): 738–742, 2004.
  4. Juergens, U.R., Dethlefsen, U., Steinkamp, G., Gillissen, A., Repges, R., and Vetter, H. "Anti-inflammatory activity of 1,8-cineol (eucalyptol) in bronchial asthma: a double-blind placebo-controlled trial." Respiratory Medicine, 97(3): 250–256, 2003.
  5. Hendry, E.R., Worthington, T., Conway, B.R., and Lambert, P.A. "Antimicrobial efficacy of eucalyptus oil and 1,8-cineole alone and in combination with chlorhexidine digluconate against microorganisms grown in planktonic and biofilm cultures." Journal of Antimicrobial Chemotherapy, 64(6): 1219–1225, 2009.
  6. Bachir, R.G. and Benali, M. "Antibacterial activity of the essential oils from the leaves of Eucalyptus globulus against Escherichia coli and Staphylococcus aureus." Asian Pacific Journal of Tropical Biomedicine, 2(9): 739–742, 2012.
  7. Mulyaningsih, S., Sporer, F., Zimmermann, S., Reichling, J., and Wink, M. "Synergistic properties of the terpenoids aromadendrene and 1,8-cineole from the essential oil of Eucalyptus globulus against antibiotic-susceptible and antibiotic-resistant pathogens." Phytomedicine, 17(13): 1061–1066, 2010.
  8. Tyagi, A.K. and Malik, A. "Antimicrobial potential and chemical composition of Eucalyptus globulus oil in liquid and vapour phase against food spoilage microorganisms." Food Chemistry, 126(1): 228–235, 2011.
  9. Worth, H., Schacher, C., and Dethlefsen, U. "Concomitant therapy with cineole (eucalyptol) reduces exacerbations in COPD: a placebo-controlled double-blind trial." Respiratory Research, 10(1): 69, 2009.
  10. Serafino, A., Vallebona, P.S., Andreola, F., Zonfrillo, M., Mercuri, L., Federici, M., Rasi, G., Garaci, E., and Pierimarchi, P. "Stimulatory effect of eucalyptus essential oil on innate cell-mediated immune response." BMC Immunology, 9: 17, 2008.
  11. Trivedi, N.A. and Hotchandani, S.C. "A study of the antimicrobial activity of oil of Eucalyptus." Indian Journal of Pharmacology, 36(2): 93–95, 2004.
  12. Elaissi, A., Rouis, Z., Salem, N.A.B., Mabrouk, S., Salem, Y.B., Salah, K.B.H., Aouni, M., Farhat, F., Chemli, R., Harzallah-Skhiri, F., and Khouja, M.L. "Chemical composition of 8 eucalyptus species' essential oils and the evaluation of their antibacterial, antifungal and antiviral activities." BMC Complementary and Alternative Medicine, 12: 81, 2012.
  13. Tibballs, J. "Clinical effects and management of eucalyptus oil ingestion in infants and young children." Medical Journal of Australia, 163(4): 177–180, 1995. PubMed PMID: 7651249
  14. Suresh, D., VijayaKumar, S., Pradhan, P., and Balasubramanian, S. "Fatal eucalyptus oil poisoning in an adult male: a case report with comprehensive autopsy and histopathological findings." Cureus, 17(4): e83053, 2025. PubMed PMID: 40432665
  15. Darben, T., Cominos, B., and Lee, C.T. "Topical eucalyptus oil poisoning." Australasian Journal of Dermatology, 39(4): 265–267, 1998. PubMed PMID: 9838728
  16. Duisken, M., Sandner, F., Blömeke, B., and Hollender, J. "Metabolism of 1,8-cineole by human cytochrome P450 enzymes: identification of a new hydroxylated metabolite." Biochimica et Biophysica Acta, 1722(3): 304–311, 2005. PubMed PMID: 15715982
  17. Salari, M.H., Amine, G., Shirazi, M.H., Hafezi, R., and Mohammadypour, M. "Antibacterial effects of Eucalyptus globulus leaf extract on pathogenic bacteria isolated from specimens of patients with respiratory tract disorders." Clinical Microbiology and Infection, 12(2): 194–196, 2006. PubMed PMID: 16441463

PubMed Topic Searches

The following PubMed topic searches aggregate the peer-reviewed literature underpinning the claims above. Each link opens a live PubMed query so the result set stays current as new research is published.

  1. PubMed: Essential oil antimicrobial
  2. PubMed: 1,8-cineole eucalyptol bronchitis
  3. PubMed: Respiratory clinical trial
  4. PubMed: Sinusitis and rhinosinusitis
  5. PubMed: Asthma and COPD
  6. PubMed: Antifungal activity against Candida
  7. PubMed: Anti-inflammatory mucolytic
  8. PubMed: Analgesic and pain
  9. PubMed: Insect repellent
  10. PubMed: Systematic review
  11. PubMed: Oil safety and toxicity

Back to Table of Contents

Connections

Back to Table of Contents